Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 TrialXavier Thomas, D Fière, Tibor Kovacsovics et al.|Journal of Clinical Oncology|2004Cited by 547
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trialJörge E. Cortes, Mark J. Levis, Alexander E. Perl et al.|The Lancet Oncology|2018Cited by 268
Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trialEmmanuelle Tavernier, Xavier Thomas, JM Boiron et al.|Leukemia|2007Cited by 258